What Happened: Bluebird Bio said the data showed sustained treatment effect, reduced iron management burden and improved quality of life measures in patients with beta-thalassemia who require regular red blood cell transfusions following treatment with betibeglogene autotemcel, which is FDA approved in the U.S. and marketed as ZYNTEGLO.

"Long-term results presented at ASH 2023 showed durable transfusion independence and a continued positive safety profile in patients with beta-thalassemia treated with our beti-cel gene therapy through up to nine years of follow-up," said Richard Colvin, chief medical officer of Bluebird Bio.

The news comes after Bluebird Bio shares tumbled on Friday after the FDA added a black box warning for patients treated with Lyfgenia regarding the risk of hematologic malignancy.

See Also: Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease

BLUE Price Action: Bluebird Bio shares were up 2.45% at $2.93 at the time of publication, according to Benzinga Pro.

Photo: 3844328 from Pixabay.